Abstract-The effects of a novel compound, 6-(10-hydroxydecyl)-2,3-dimethoxy 5-methyl-l,4-benzoquinone (idebenone, CV-2619), on cerebral and renal vascular changes were examined in stroke-prone spontaneously hypertensive rats (SHRSP) and in rats with experimentally induced hypertension.
CV-2619 (35 mg/kg/day, p.o.) significantly inhibited the onset of cerebrovascular lesions (stroke) and the elevation of blood pressure in SHRSP with mild hypertension . A higher dose (2 x 50 mg/kg/day, p.o.) clearly delayed the onset of both stroke and proteinuria without any effect on the blood pressure in SHRSP with severe hypertension . In DOCA-salt hypertensive rats, CV-2619 (2x5 or 2x25 mg/kg/day , p.o.) dose dependently inhibited decreases in body weight and water balance and the develop ment of cerebral and renal vascular changes.
These results suggest that CV-2619 inhibits the development of stroke and renal vascular lesions in hypertensive rats.
Arterial narrowing and endothelial cell damage appear to be the initial changes seen in vascular lesions related to hypertension. At advanced stages of hypertension, these vascular changes lead to a decrease in blood flow in organs such as the brain and kidneys. The hemodynamic alterations cause metabolic changes in vascular and organ tissues and subsequently, severe damage such as fibrinoid necrosis and degeneration of the arterial wall (1) . These processes are likely to be an important sequence of cerebro vascular lesions (stroke), as can be demon strated using stroke-prone spontaneously hypertensive rats (SHRSP) (2, 3) . We recently indicated that there was a close relation between renal ischemia induced by vascular changes and the onset of stroke in the SH RSP (4). These renal vascular changes lead to altered electrolyte metabolism through changes in intrarenal hemodynamics and tubular function, which are risk factors in hypertensive vascular lesions. Therefore , drugs that overcome the metabolic changes induced by ischemia may have an inhibitory action on the development of hypertensive vascular lesions.
We have now examined the effects of a novel compound, 6-(10-hydroxydecyl)-2,3 dimethoxy-5-methyl-l,4-benzoquinone (idebenone, CV-2619), on vascular lesions in the brain and kidneys in rats with spontaneous or experimentally induced hypertension; the results are presented here.
Materials and Methods
Stroke-prone spontaneously hypertensive rats (SHRSP) (5) and Wistar-Kyoto rats treated with desoxycorticosterone acetate (DOCA) and salt were used under controlled conditions of temperature (23-25°C), humidity (50-60%), and light (7:00-19:00) in the barrier system of an animal room. In allocating SHRSP rats into control and drug-treated groups, an equal number of animals from a litter were assigned to each group, because the vulnerability for stroke varies somewhat between litters (5).
SHRSP rats: Male SHRSP rats were raised in our laboratories and given laboratory chow (CE-2, Japan Clea) and tap water ad libitum until 8 weeks of age. Thereafter, these rats were housed in isolation cages and fed on a powdered CE-2 diet to which 2% NaCI was added during the experimental period. The final concentration of sodium in the diet was 48.8 meq/100 g. The high salt diet accelerated the onset of stroke and reduced the distribution of its onset time (6) . In the salt-loaded SHRSP, two experiments were done. In the first, SHRSP with mild hypertension (blood pressure at the start of experiment was about 175 mmHg) were divided into control (n=12) and CV-2619 treated (n=1 2) groups. CV-261 9 was admin istered for 40 days admixed with the powder diet in a concentration of 0.05% (w/w). The average daily dose of the compound during the experimental period was 35 mg/kg. In the second experiment, SHRSP with severe hypertension (blood pressure at the start of drug administration was about 220 mmHg) was used, and CV-2619 (50 mg/kg) sus pended in 5% arabic gum solution was orally administered by gavage twice a day (8:30 and 16:00). The administration of the drug was started after the blood pressure had increased to the critical level (220 mmHg), beyond which stroke will occur frequently in SHRSP (7) .
DOCA-salt hypertensive rats: This type of hypertension was produced using normal male Wistar-Kyoto rats, aged 7 weeks. In this experiment, 4 groups of rats were examined: group 1 was a normotensive control (n=8), group 2 was a hypertensive control (n=8), group 3 consisted of hyper tensive rats administered a low dose (5 mg/ kg twice a day) of CV-261 9 (n=8), and group 4 consisted of hypertensive rats administered a high dose (25 mg/kg twice a day) of CV 2619 (n=8). The left kidney in all rats was removed under sodium pentobarbital anes thesia (50 mg/kg, i.p.) to accelerate the elevation of blood pressure induced by DOCA and salt. DOCA (10 mg/kg) suspended in 5% arabic gum solution was given subcu taneously to the hypertensive groups of rats (groups 2-4) on the operation day and 7, 14 and 21 days after the operation. A 5% arabic gum solution without DOCA was similarly injected into normotensive control rats, with the same schedule. During the experimental period, all the rats were given laboratory chow (CE-2) and a 1 % NaCI solution of drinking water ad libitum. CV-2619 (5 or 25 mg/kg) suspended in the arabic gum solution was administered by gavage twice daily for 2 weeks. On day 24, all rats were decapitated, and their brains and kidneys were examined for histological changes.
Blood pressure measurement and urinary protein assay: Systolic blood pressure in the tail artery was measured once or twice a week (7). Blood pressure was not measured in rats with signs of stroke because it oscillated with the development of signs of stroke. Twenty four hr urine samples were collected once or twice a week on the day before blood pressure measurement using the isolation cages, and total protein excretion was determined by a biuret method (8) . When the level of urinary protein was over 100 mg/day per 250 g body wt., this was considered as "proteinuria", since the normal level of urinary protein was found to be 30-50 mg/day in Wistar-Kyoto rats and SHRSP rats (4). Fluid intake and urinary volume were also measured, and the difference (fluid intake urinary volume) was considered as the water balance in the DOCA-salt hypertensive rats. Vascular changes in the brain and kidney: In SHRSP, the development of stroke was predicted by stroke-signs such as stereotyped lifting of arms, behavioral depression, and hyperirritability, and was confirmed by autopsy 5 days after the development of the signs (5, 7). The cerebral hemorrhage and hemorrhagic infarction were extensive enough for macroscopic detection.
Renal vascular changes were inferred from the amount of urinary protein excretion, as the amount of protein parallels the severity of the renal vascular changes in SHRSP (4, 6).
The brains and kidneys were fixed with 10% neutral formaldehyde solution. The tissues were embedded in paraffin, cut to a thickness of 5 icm and stained with hematoxylineosin.
Statistical analysis: Data were expressed as the mean+S.E.
Analysis of variance (whole significant difference method) was used for statistical analysis of all values, except for the results of the pathology which were compared using Wilcoxon's two-sample test or a two-tailed x2 test. Fig. 1 . Effect of CV-261 9 (35 mg/kg/day) on body weight, systolic blood pressure and incidence of stroke in stroke-prone spontaneously hypertensive rats (SHRSP). The drug was administered admixed with a powdered diet for 40 days. The incidence of stroke is expressed cumulatively, ar,d the statistical difference was analyzed by Wilcoxon's two sample test. 0: control, •: CV-261 9 treated group. n=12. Mean±S.E. *P<0.05 vs. control. Systolic blood pressure in the SHRSP was about 175 mmHg at the start of the experiment. As shown in Fig. 1 , CV-261 9 (35 mg/kg/day) had a mild antihypertensive action. A significant difference between the control and treated groups (n=12) was observed at the 2nd, 3rd and 5th weeks, but not at the 4th and 6th weeks. The onset of stroke was observed from the 18th day after the start of the experiment in the control and from the 23rd day in the treated group (Fig. 1) . Thereafter, the cumulative incidence of stroke increased in the two groups. CV-2619 partially, but significantly (P<0.05), inhibited the onset of stroke; the onset of stroke in the drug-treated group was significantly delayed compared with that in the control group. The compound tended to inhibit the reduction in growth rate at the advanced stage of hypertension.
2. Effects on blood pressure, development of proteinuria and stroke in SHRSP with severe hypertension:
In this experiment, the administration of CV-2619 (50 mg/kg, p.o. twice daily) was started when the average blood pressure in the control and CV-2619 treated groups (n=10) reached the level of severe hypertension (220 mmHg). In cases of severe hypertension, CV-2619 showed no significant effect on the blood pressure in the SHRSP, although the dose in this experiment was higher than that in the first experiment (Fig. 2) . However, the compound clearly delayed the onset of proteinuria and stroke (Fig. 3) . The compound also inhibited the reduction in growth rate in the later stages of the experiment (Fig. 2) . Urinary volume did not differ significantly between the two groups, though the increase in urinary volume during the stage of severe hypertension tended to be inhibited by CV-2619. For example, the volume was 25.4±3.2 (n=7) and 18.5±1.0 ml/day per 250 g body wt. on day 36 in the control and the treated groups, respectively. Fig. 3 . Effects of CV-261 9 (50 mg/kg, twice daily) administered orally after the development of severe hypertension on incidences of proteinuria and of stroke in SHRSP. Incidence is expressed cumula tively. Statistical difference was analyzed by Wilcoxon's two sample test. n=10. Fig. 4 . Effects of CV-2619 (2x5 or 2x25 mg/kg/ day) on body weight changes in DOCA-salt hyper tensive rats. For comparative purposes, the growth curve in normotensive control rats is shown. *P<0.05 between hypertensive control group (control) and CV-2619 treated group. n=8. Mean±S.E. In the CV-2619 treated groups, the decrease in body weight observed in the hypertensive control rats was inhibited by the administration of the high dose (2x25 mg/ kg/day) of the drug; the low dose (2 x 5 mg/ kg/day) was not effective. Furthermore, the high dose of CV-2619 slightly inhibited the elevation of blood pressure and markedly ameliorated the increase in protein excretion.
The change in protein excretion in each group was associated with changes in urinary volume and water balance. Fluid intake and urinary volume were time-dependently in creased in the hypertensive control group (Table  1) . CV-2619 (2x25 mg/kg/day) significantly reduced the increases in fluid intake and urinary volume. Water balance was decreased in the hypertensive control group, and the high dose of CV-261 9 also inhibited this decrease.
4. Effects on vascular changes in DOCA salt hypertensive rats: The results of macro scopic observation at autopsy are shown in Table 2 . Normotensive control rats did not show any macroscopic changes in the brain and kidney. In contrast, in the hypertensive control group, hemorrhagic change and/or leakage of Evans blue were detected in the cerebral cortex, and mild or severe nephro sclerotic changes (granular and pale changes on the surface) were observed in the kidneys of almost all of the rats. CV-261 9, especially its high dose (2x25 mg/kg/day), inhibited these changes in the brain and kidney. The incidence of the renal changes more severe than grade 2+ was significantly (P<0.01) lower in the high dose group (3/8) than in the hypertensive control group (8/8). Hydro thorax and ascites occurred in some rats; the incidence of the former in the hyper tensive control, the low dose, and the high dose groups were 5/8, 3/8 and 1/8, respec tively, and of the latter, 5/8, 4/8 and 1/8, respectively. (Table 3) and kidney (Table 4 ). In the hypertensive control group, edema and microhemorrhage in the cerebral cortex (Fig.  7) were observed in almost all the rats. The high dose of CV-261 9 significantly (P<'0.05) reduced the incidence of marked edema and of microhemorrhage in the cerebral cortex, but the low dose of CV-261 9 did not. Table 2 . Macroscopic findings obtained at autopsy in DOCA-salt hypertensive control and CV-2619 (2 x 5 or 2 X 25 mg/kg/day) treated rats Table 3 . Histological changes in the brain from DOCA-salt hypertensive control and CV-2619 (2x5 or 2x25 mg/kg/day) treated rats In all rats with cerebral edema, fibrinoid necrosis was present in the cortical penetrating arteries (Fig. 7) . Microhemorrhage in the thalamus or hypothalamus was also observed in one rat of the hypertensive control group and the group receiving the low dose of CV-2619. Table 4 . Histological changes in the kidneys from DOCA-salt hypertensive control and CV-261 9 (2 x 5 or 2 x 25 mg/kg/day) treated rats Discussion Under conditions of salt-loading, the blood pressure of stroke-prone spontaneously hypertensive rats (SHRSP) rapidly elevated. Thereafter, there was an increase in urinary excretion of protein, mainly related with renal vascular changes, and subsequently, stroke occurred.
These pathophysiological sequences accorded well with our previous findings (4, 6, 9) . The increase in urinary protein was closely associated with ischemic changes such as necrotic and degenerative changes in the glomerular afferent arterioles and interlobular arteries and the glomerulus (4, 6) . It has been speculated that a decrease in renal blood flow (renal ischemia) may be a causative factor of cerebrovascular changes in SHRSP (4) . On the other hand, in the brain of SHRSP, a reduction in local cerebral blood flow was observed before the stroke occurred (3). These findings suggest that ischemia in the brain itself and/or renal dysfunction due to ischemic changes in the afferent arterioles play an important role in the development of the cerebrovascular lesions.
CV-2619 slightly inhibited the elevation of blood pressure in SHRSP with mild hyper tension, but not in SHRSP with severe hypertension.
The compound significantly delayed the onset of stroke in the SH RSP with either form of hypertension and the onset of proteinuria in the SH RSP with severe hyper tension. These results suggest that CV-2619 inhibits the development of stroke and renal vascular lesions in SHRSP.
The administration of DOCA and salt to normal rats led to a rapid elevation of blood pressure and a malignant hypertension. Gavras et al. (10) reported that in DOCA salt hypertensive rats, a positive sodium balance was observed in the benign hyper tensive stage, and a negative sodium balance was observed in the malignant hypertensive stage. Also, in the present study, increases in intake of drinking water (11% NaCI), urinary volume and protein excretion were observed in the hypertensive controls, especially in the later stages. Furthermore, vascular changes in the brain and kidney were evident in almost all the hypertensive controls. The main vascular changes were fibrinoid necrosis mainly in the glomerular afferent arteriole of the kidney and in the penetrating artery of the brain. Microhemorrhage and edema were also observed in the brain. CV-261 9 inhibited the increase in protein excretion, the occurrence in renal vascular changes, and the subsequent decrease in water balance. The drug also decreased the accumulation of body fluid in the thoracic and abdominal cavities. In the brain of DOCA-salt hypertensive rats, CV 2619 prevented the development of micro hemorrhage and edema in the cortex. Thus, CV-261 9 has a mild but significant inhibitory effect on the onset of hypertensive vascular changes in the brain and kidney of both types of hypertensive rats.
The mechanism by which CV-2619 inhibits the hypertensive vascular changes may not be due to the drug's mild anti hypertensive action only, because it clearly inhibited the vascular changes in the SHRSP with severe hypertension, while it did not reduce blood pressure markedly. The slight antihypertensive action of the drug observed in SHRSP with mild hypertension and in DOCA-salt hypertensive rats seems to be secondary to its inhibitory action on the development of vascular changes, because the drug did not show a primary hypotensive action in either type of hypertensive rats, in the early periods of the experiments.
Finally, CV-2619 inhibited the develop ment of renal vascular changes (proteinuria in SHRSP) in SHRSP and DOCA-salt hyper tensive rats (Fig. 3 and Table 4 ). This action of the compound may partly be related to its preventive effect on the onset of cerebro vascular lesions, because renal ischemia following changes in the afferent arterioles was implicated in the occurrence of stroke in SHRSP (4).
